Skip to main content
Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)Children's healthDrugPhase 3

What this study is

The main purpose of this study is to evaluate the efficacy and safety of lebrikizumab in participants with chronic rhinosinusitis and nasal polyps treated with intranasal corticosteroids. The study will last about 18 months.

What's being tested

  • LY3650150

    Intervention · DRUG

  • Placebo

    Intervention · DRUG

  • Standard therapy for INCS

    Intervention · DRUG

    Administered as intranasal spray.

Both LY3650150 and Placebo

Administered SC.

Study details

Official title
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lebrikizumab/LY3650150 in Participants With Chronic Rhinosinusitis With Nasal Polyps on Background Intranasal Corticosteroids
Sponsor
Eli Lilly and Company
Conditions
Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Enrolling
510 people
Starts
2024-04-29
Est. completion
2028-03
Design
Quadruple-blind, randomized, parallel groups, Phase 3
Record
View on ClinicalTrials.gov ↗